Evaluating the Effectiveness of NOAC and LMWHs in Reducing Mortality in Critically Ill Patients with COVID-19 DOI Creative Commons
Rubens Costa Filho,

Amarino Carvalho de Oliveira,

Felipe Saddy

et al.

Research Square (Research Square), Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 7, 2024

Abstract Background Severe COVID-19 is associated with increased prothrombotic and inflammatory responses, necessitating effective anticoagulation therapy. Novel oral anticoagulants (NOACs) are being explored as alternatives to low-molecular-weight heparin (LMWH). Methods This retrospective cohort study compared the effectiveness safety of NOACs LMWH in reducing mortality among 76 critically ill, unvaccinated patients confirmed SARS-CoV-2 infection. The included 41 treated 35 during their ICU stay. primary outcomes focused on mortality, secondary including deep vein thrombosis (DVT), bleeding episodes, transfusion rates. Results Baseline characteristics, demographic data severity scores, were similar between groups (mean age: LMWH, 74.5 ± 15.1 years [59% male]; NOAC, 71.6 14.8 [60% male]). Mortality was significantly greater group (51.21% [95% confidence interval (CI): 36.4–65.7]) than NOAC (20% CI: 10.0–35.9]; p = 0.005), standardized ratios 1.61 0.71, respectively (p 0.004). Elevated D-dimer levels strongly risk. DVT occurred 9.76% 5.71% 0.68). rates comparable groups. Conclusions a lower rate LMWHs ill patients, reflecting an 81% reduced risk death. These findings highlight potential advantages managing severe underscore need for further research optimize therapy improve patient outcomes.

Language: Английский

O Imenso Desafio de Buscar a Melhor Evidência DOI Creative Commons
Luiz Maurino Abreu

Arquivos Brasileiros de Cardiologia, Journal Year: 2024, Volume and Issue: 121(3)

Published: Jan. 1, 2024

Citations

0
The Immense Challenge of Searching for the Best Evidence DOI Creative Commons
Luiz Maurino Abreu

Arquivos Brasileiros de Cardiologia, Journal Year: 2024, Volume and Issue: 121(3)

Published: Jan. 1, 2024

Language: Английский

Citations

0
Evaluating the Effectiveness of NOAC and LMWHs in Reducing Mortality in Critically Ill Patients with COVID-19 DOI Creative Commons
Rubens Costa Filho,

Amarino Carvalho de Oliveira,

Felipe Saddy

et al.

Research Square (Research Square), Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 7, 2024

Abstract Background Severe COVID-19 is associated with increased prothrombotic and inflammatory responses, necessitating effective anticoagulation therapy. Novel oral anticoagulants (NOACs) are being explored as alternatives to low-molecular-weight heparin (LMWH). Methods This retrospective cohort study compared the effectiveness safety of NOACs LMWH in reducing mortality among 76 critically ill, unvaccinated patients confirmed SARS-CoV-2 infection. The included 41 treated 35 during their ICU stay. primary outcomes focused on mortality, secondary including deep vein thrombosis (DVT), bleeding episodes, transfusion rates. Results Baseline characteristics, demographic data severity scores, were similar between groups (mean age: LMWH, 74.5 ± 15.1 years [59% male]; NOAC, 71.6 14.8 [60% male]). Mortality was significantly greater group (51.21% [95% confidence interval (CI): 36.4–65.7]) than NOAC (20% CI: 10.0–35.9]; p = 0.005), standardized ratios 1.61 0.71, respectively (p 0.004). Elevated D-dimer levels strongly risk. DVT occurred 9.76% 5.71% 0.68). rates comparable groups. Conclusions a lower rate LMWHs ill patients, reflecting an 81% reduced risk death. These findings highlight potential advantages managing severe underscore need for further research optimize therapy improve patient outcomes.

Language: Английский

Citations

0